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Abstract 
The incidence of lung cancer continues to rise worldwide. Because the aggressive metastasis of lung cancer cells is 
the major drawback of successful therapies, the crucial challenge of modern nanomedicine is to develop diagnostic 
tools to map the molecular mechanisms of metastasis in lung cancer patients. In recent years, microfluidic plat‑
forms have been given much attention as tools for novel point‑of‑care diagnostic, an important aspect being the 
reconstruction of the body organs and tissues mimicking the in vivo conditions in one simple microdevice. Herein, 
we present the first comprehensive overview of the microfluidic systems used as innovative tools in the studies of 
lung cancer metastasis including single cancer cell analysis, endothelial transmigration, distant niches migration and 
finally neoangiogenesis. The application of the microfluidic systems to study the intercellular crosstalk between lung 
cancer cells and surrounding tumor microenvironment and the connection with multiple molecular signals coming 
from the external cellular matrix are discussed. We also focus on recent breakthrough technologies regarding lab‑
on‑chip devices that serve as tools for detecting circulating lung cancer cells. The superiority of microfluidic systems 
over traditional in vitro cell‑based assays with regard to modern nanosafety studies and new cancer drug design and 
discovery is also addressed. Finally, the current progress and future challenges regarding printable and paper‑based 
microfluidic devices for personalized nanomedicine are summarized.
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Introduction
Microfluidic and nanofluidic are terms that refer to engi-
neered manipulation of fluid flow that is geometrically 
constrained to micro-[1] and nanosized objects [2]. These 
microfluidic and nanofluidic systems are miniaturized 
devices that are becoming mainstream tools having the 
potential to recapitulate complex biological processes 
in  vitro and thus influence the improvement of cancer 
diagnostic and basic cancer research [3–5]. Microfluidic 
systems have revolutionized three-dimensional (3D) cul-
ture techniques [6] and gained greater popularity over 
traditional two-dimensional (2D) cell culture approaches 
due to greater ability to reproduce in  vivo environment 
present inside the human body. 3D microfluidic devices 
in comparison to 2D systems enable fluid manipulation 
[7], maintaining a controllable temperature [8] and con-
ditions of fresh medium supply [9], shear flow pressure 
[8, 10] and chemical gradients [6, 11] essential for mim-
icking processes and mechanism taking place in vivo. The 
materials that they are made of provide different grades 
of stiffness and may be permeable to oxygen affecting 
cell adhesion, migration, and proliferation [6]. Moreo-
ver, microfluidic devices can integrate multiple pro-
cesses such as cell culture handling [6, 12], cell behaviour 
tracking [13] by real time monitoring [14], simultane-
ous analysis of several studied groups [9] as well as cell 
capture [15], lysis [16], detachment [6, 12], mixing [17], 
and detection [6, 12, 18]. Special properties of micro-
fluidic devices are the possibility of self-organisation 
in multilayer cellular structures [19] and allowing sig-
nal transduction between cells, with the extracellular 
matrix (ECM) and other systemic factors [12] imitating 
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The beginning of the exploration of microfluidic devices 
is traced to early 90 s and is currently rapidly progressing. 
According to Grand View Research [20] and Markets and 
Markets [21] the worldwide microfluidics market size 
was estimated at approximately USD 2.5 billion in 2016 
and USD 10.06 billion in 2018, respectively. Both, Grand 
View Research and Markets and Markets expect that the 
market will expand at a Compound Annual Growth Rate 
(CAGR) of around 18.4% before 2024 [20] and 22.6% 
before 2023 [22], respectively, reaching USD 27.91 bil-
lion by 2023 [22]. The microfluidic devices are getting 
more and more popular compared to traditional size 
equipment due to lower power and time consumption, 
wider flexibility [23], minimized sample and reagents 
consumption [4], reduced manufacturing and handling 
costs [24] along with keeping the features of rapid sample 
processing [4], automation [24] high throughput screen-
ing, high resolution and high accuracy [8] as in the tradi-
tional ones. The potential of microfluidic devices has also 
been noticed by well-known companies like Abbott [20], 
Merck [25], Roche Diagnostics [20], Ibidi [26], Cepheid, 
Becton and Dickinson and Company (BD) [20], which 
provide microfluidic devices. There are also companies 
developed quite recently, specialized in nanotechnology 
and microfluidics production such as Darwin Microfluid-
ics [27], Micronit [28], uFluidix [29], Elvesys [30], Micra-
lyne [31] and Dolomite [32]. The increasing demand 
of microfluidic systems is also reflected in the growing 
amount of papers concerning engineering of new micro-
devices and their applications (Fig. 1).
The microfluidic platforms were able to evolve as a 
result of novel micro/nanofabrication technologies based 
on different soft lithography techniques [35, 36]. These 
techniques allow to manufacture the physical objects 
with dimensions measured in micro- and nanometer 
scales [37]. Most of the microfluidic devices comprise 
of chambers [38], channels [39] and other structures 
such as pillars [40], rods, tubes and wires fabricated as 
small nanoscale objects [41, 42]. The application of these 
nanoscale elements in one microfluidic device enables to 
observe the cancer cells behavior in response to a variety 
of factors and stimuli in real-time.
The development of microfluidic techniques is pre-
dominantly noticeable in relation to micro-engineering 
devices used for the separation of circulating tumor cells 
(CTCs). Until recently, most of the microfluidic tests for 
Fig. 1 Increased publication trend on microfluidics used in cancer studies in the years 2005–2018. Data were collected based on PUBMED and NCBI 
databases. The insert presents the estimated and expected worth of the microfluidic market in billion USD based on PR Newswire [33], Grand View 
Research [20], Markets and Markets [22] and Mordor Intelligence [34] estimations
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CTCs enrichment and enumeration were based on the 
immune-affinity and size-dependent methods commonly 
used for cancer cell separation [42]. The breakthrough in 
engineering of the microfluidic systems is the possibility 
of impedance measurement of each captured cancer cell. 
Because the dielectric signal obtained from each exam-
ined cell has some specific properties, such an approach 
permits better distinguishing the cancer cell from other 
type of cells including blood cells [43].
More sophisticated and advanced microfluidic-based 
platforms are continuously developed. The latest chips 
are even capable of biomimicking some biological pro-
cesses, such as metastasis [44] and recapitulating the 
physiological activities of entire organs [45] and of the 
human body [46]. This revolutionary approach in point-
of-care (POC) diagnostics allows a detailed study of sim-
ple mechanisms at the cellular level, as well as of complex 
processes involved in diverse tissues and organs. Moreo-
ver, microfluidic systems may also serve as a platform for 
drug development and nanosafety assays (Fig. 2) [45, 46]. 
The development of microfluidic techniques may con-
tribute to the reduction of animal models’ use in cancer 
research, and more importantly overcome the interspe-
cies limitations in new anticancer drug investigations.
Lung cancer is a leading cancer worldwide [47]. 
According to the American Cancer Society, at least 85% 
of the total cases of lung cancers refer to non-small cell 
lung cancer (NSCLC), 10–15% to small cell lung cancers 
(SCLC), and approximately 2% to lung carcinoid tumors 
[48–50]. Studies evidence that lung cancer often metas-
tasizes to distant parts of the lung and other organs like 
bones, brain, liver [51], breast [52], colon [53], kidney 
[54], and many others [44]. The American Lung Associa-
tion informs the public that the survival rate in patients 
with metastatic lung cancer is lower comparing to other 
leading cancers. The 5-years survival rate for lung cancer 
without metastasis accounts for 55% [55], while for meta-
static lung cancer accounts for approximately 4% [56]. 
The aggressive progression of lung cancers [47], resist-
ance to chemotherapy [57] and high mortality ratio in 
cancer patients has recently drawn attention of scientists 
to thoroughly investigate and identify the mechanism of 
lung cancer development in order to develop targeted 
therapies.
Here we present the first comprehensive overview of 
microfluidic systems and their applications for studying 
the complex biological mechanisms that occur during 
lung cancer metastasis. The review also outlines recent 
scientific achievements regarding metastatic processes 
and advancements in anticancer drug development. It 
also presents nanosafety issues in modern nanomedicine.
The metastatic process of tumor cancers
Metastasis is a sequence of cellular and molecular events 
leading to cancer outgrowth in distant sites and organs 
of the body. This process is launched from the dissemi-
nation of primary tumor cells that undergo transforma-
tion, acquiring aggressive traits like ability to move and 
penetrate into the extracellular matrix, resulting in the 
development of secondary tumors [58, 59]. Briefly, it is a 
complex and multi-stage process that is initiated by the 
cancer cells’ breakaway from the tumor tissue (epithe-
lial–mesenchymal transition), subsequent cancer cells 
intravasation, survival within the bloodstream and cells’ 
migration toward various sites in the organism, extrava-
sation and development of metastatic foci [58, 60–62]. 
This aggressive and invasive process is the final conse-
quence of a bi-directional communication between the 
Fig. 2 Microfluidic device for nanotoxicity testing originally designed in the GEMNS project (EuroNanoMed II program) by the Nanotoxicology 
group at the University of Bergen, Norway. Microfluidic set‑up. A The microfluidic chip comprises four independent microfluidic channels (blue). 
Cells growing within the microfluidic channel are analyzed via cell‑substrate electrical impedance using microelectrode arrays (gold) (scale bar, 
5 mm). B Mounted microfluidic chip. On‑chip liquid reservoirs (red dots), tubing from syringe pumps (red arrows), electrical contacts (yellow arrows) 
and tubing providing humidified air/CO2 are connected to the chip
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cancer cells and the surrounding tumor microenviron-
ment that is manifested by a tumor microenvironment 
evolution responding to disease initiation and progres-
sion towards the invasion stages [60].
The initiation of the metastasis process is conditioned 
by many factors including gene expression and cellular 
components. Cells with metastatic potential feature high 
heterogeneity due to genetic alteration involving chromo-
somal reorganizations, DNA mutations and epigenetic 
modifications. Such genes undergo expression at the late 
state of cancer development, which can be explained by 
gaining invasive traits for seeding at distant sites [63]. 
The extreme importance in metastasis initiation and 
progression is the intercellular crosstalk between cancer 
cells and the surrounding tumor microenvironment. In 
the first stages of metastasis, disruption of cell–cell adhe-
sion mediates uncontrolled cell growth promotion and 
cancer cells’ dissemination. In this catenin-dependent 
process cells undergo epithelial–mesenchymal transfor-
mation gaining migratory abilities [64]. Once the can-
cer cells obtain the ability to move away they invade the 
adjacent extracellular matrix (ECM) and intravasate into 
blood stream and lymphatic system. This process is sup-
ported by cytokines, growth factors, matrix metallopro-
teinases (MMPs), integrins, actin binding proteins and 
chemokines [62, 63] frequently mediated by tumor-shed 
exosomes [65]. The tumor-associated stroma cells such 
as macrophages, fibroblasts, vascular space-related cells, 
and various immune responses are also involved as they 
are governed by the state of tumor progression [63, 66]. 
The stromal cells further enhance the aggressive behavior 
of carcinoma cells through various heterotypic signaling 
such as IL-6,  CD4+ and IL-4 [59].
Reaching the circulatory system by tumor-derived cells 
through the intravasation process is mostly associated 
with their quick destruction, among others due to exposi-
tion to shear stress in the vasculature. Therefore, less than 
0.1% of circulating tumor cells are capable to form sec-
ondary tumors. Probably, the ability to survive belongs 
to those CTCs that underwent epithelial–mesenchymal 
transition (EMT) and evaded the anoikis processes [67, 
68]. The CTCs mostly spread out through blood or lym-
phatic vessels, however there are also other ways such as 
transcoelomic dissemination into the pleural, pericardial, 
and abdominal cavities [67]. In a place where the blood 
flow is reduced, CTCs adhere to vascular endothelium, 
express adhesion molecules and lunch the production 
of holes in endothelia for escaping from vasculature 
towards the preferred organ [68]. The selection of the 
susceptible metastatic organ was revealed to be associ-
ated with tumor-induced determination of the microen-
vironment, named pre-metastatic niches (PMNs). The 
PMNs initiation and organization prior to CTCs seeding 
involves various environmental components, signaling 
factors and tumor-secreted vesicles [69]. In the case of 
disseminated lung cancer cells, their main places of desti-
nation are thought to be the brain, bones, adrenal glands 
and liver [70].
Once the cancer cells undergo rapid growth in the 
invaded tissue the colonization is already initiated in 
the distant organ. Angiogenesis and lymphangiogenesis 
have a pivotal meaning in this step. New vasculature 
formation is started by local injuries in the basement 
membrane by rapid destruction and hypoxia processes. 
Subsequently, endothelial cells migrate and proliferate, 
mediated by angiogenic factors, since tumor requires 
constant nutrition and oxygen supply [71]. The microflu-
idic devices applied to study the different stages of lung 
cancers metastasis described in this overview are pre-
sented in Fig. 3.
Dissemination from the primary tumor
The epithelial–mesenchymal transition is the key point 
for cancer cells moving out from the primary tumor. Dur-
ing this process the cells acquire migratory abilities that 
make them capable of invading local and distant tissues 
[60]. Losing of cell polarity, rearrangement of cell–cell 
junctions, cells elongation and gaining of a fibroblast-
like morphology are elements of a multistep EMT pro-
cess that is modulated by extracellular signaling factors 
including receptor tyrosine kinase (RTK), transforming 
growth factor β (TGFβ), and Notch and Wnt signaling 
pathways [62, 81]. These molecules can co-operate induc-
ing expression of transcriptional factors that subse-
quently lead to the down regulation of the epithelial 
phenotype (E-cadherin) and upregulation of the mesen-
chymal phenotype. The appearance of the mesenchymal 
phenotype is expressed by production of N-cadherin and 
vimentin. This in turns supports tumor growth, the rear-
rangement of cytoskeletal organization and supports the 
promotion of metastasis [62].
The TGFβ participations in EMT activation was 
reported in many tissues and is being considered the 
most prevalent mediator of the EMT process. Therefore, 
the regulatory mechanisms of TGFβ need deeper inves-
tigation, which is why Kim et  al. developed a microflu-
idic gradient device to reproduce the association between 
TGFβ and EMT [13]. The device involved a vacuum 
channel network and fluidic microchannels for the gener-
ation of a stable concentration gradient. The application 
of the device enabled to establish the TGFβ concentra-
tions that initiated and fully converted cells to mesenchy-
mal form. The influence of the various concentrations on 
the EMT process was analyzed by cells’ elongation moni-
toring, as well as the expression of epithelial and mesen-
chymal factors by Western blot.
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A special importance of the EMT process occur-
rence is assigned to the strength of cell adhesion. 
Recently, Li et  al. [8] constructed a microfluidic chip 
for the measurement the adhesion force of cells. The 
device consisted of a microfluidic system coupled to 
a temperature controllable perfusion apparatus and 
parameter interface. The mechanism of operation was 
based on the creation of controllable fluid shear force 
conditions within the microchannel. This device ena-
bled to investigate the adhesion capacity of A549 cells 
(adenocarcinomic human alveolar basal epithelial cells) 
on proteins being components of extracellular matrix, 
such as laminin, collagen IV, ECM Matrigel, fibronec-
tin, and 2% BSA. The adherent forces of the studied 
cells were weakest in BSA. The strength of adherence 
was rising in fibronectin, ECM Matrigel and collagen 
IV, respectively. The strongest binding was observed 
for laminin as well together with a concentration-
dependent increase of shear stress. The following step 
of investigation revealed a TGF-β interruption in the 
interaction between A549 cells and laminin in a time-
dependent fashion. In order to confirm the obtained 
results, the labeling of filamentous actin from cytoskel-
eton and vinculin, i.e., the focal adhesion protein, dur-
ing the incubation of epithelial A549 cells with TGF-β 
was performed. The loss of cell-extracellular protein 
adhesion was observed proving the launching of EMT 
process. Summing up, the device was successfully 
applied, and more than that, the constructors claimed 
that the device also possessed the ability to investigate 
the adhesion between different kinds of cells.
The mechanism of EMT was also studied by Breiman 
et  al. who investigated the participation of fucosylated 
antigen expression on the epithelial and mesenchymal 
state in cancer evolution [10]. The researchers revealed 
the relation between surface neutral α1, 2 and α1, 3/4 
fucosylated glycans and epithelial state of MCF10A cells 
with conventional methods (immunofluorescence, flow 
cytometry, qRT-PCR). They suspected that this inter-
action can be mediated by endogenous lectins, such as 
prolactin (lectin CLEC17A), hence they investigated this 
issue using the BioFlux microfluidic device. The BioFlux 
device was created for simultaneous biofilm growth with 
a controlled shear flow pressure and cells viability [73].
Fig. 3 Graphical representation of the microfluidic devices used in cancer studies described in the chapter 2. Presented microfluidic systems 
were applied to study the different stages of lung cancers metastasis. The figures are reproduced from Li et al. [8] with permission of Applied 
Biochemistry and Biotechnology, Kim et al. [13] and Xu et al. [72] with permission of Electrophoresis, Benoit et al. [73] with permission of Applied 
and Environmental Microbiology, Guo et al. [74] with permission of Biochemical and Biophysical Research Communications, Yu et al. [75] and Bai 
et al. [14] with permission of Oncotarget, Zhao et al. [47] with permission of Scientific Reports, Wang et al. [9] and Anguiano et al. [5] with permission 
of Plos One, Cui et al. [76] and Kao et al. [77] with permission of Biomicrofluidics, Zou et al. [78] with the permission of Analytical Chemistry, Tata et 
al. [38] with permission of Advances in Natural Sciences: Nanoscience and Nanotechnology, Huang et al. [39] and Li et al. [79] with permission of 
Biosensors and Bioelectronics, Li et al. [80] with the permission of Analytical and Bioanalytical Chemistry
Page 6 of 30Ruzycka et al. J Nanobiotechnol           (2019) 17:71 
Microenvironment impact on cancer metastasis
The tumor microenvironment has a great impact on 
metastasis initiation, tumor cells proliferation, and 
their further migration and colonization of distant tis-
sues [60]. An absolutely fundamental meaning has the 
recruitment of microenvironment components, such as 
tumor-associated macrophages (TAMs) and cancer-asso-
ciated fibroblasts (CAFs). Those and many others stro-
mal components, such as immune suppressor cells and 
chemokines stimulate the metastatic process [62, 82].
Tumor-associated macrophages have been reported 
to play a special role in tumor cell invasion. They derive 
from normal macrophages (M1) that possess the anti-
tumorigenic potential. Interestingly, under unknown cir-
cumstances they are capable of changing their profession 
and acquire a tumor-promoting form (M2). The M2 mac-
rophages are further subcategorized into M2a, M2b and 
M2c, based on the various factors that are responsible for 
the promotion of their polarization [14]. The M2 mecha-
nism of action in metastasis was found to be associated 
with the facilitation of tumor cells’ invasion via parac-
rine signaling. This signaling involves CSF-1, EGF and 
proteases, such as cysteine and cathepsins that enhance 
tumor progression [82]. However, the issues of mac-
rophages’ phenotype switching and their specific role in 
carcinoma cell dissemination remain unknown. Recently, 
Bai et al. constructed a three-dimensional (3D) microflu-
idic platform to investigate the relation between distinct 
TAMs in inducing EMT and cancer cells spreading [14]. 
The 3D microfluidic system incorporated a dynamic cam-
era for real-time monitoring of the interactions between 
carcinoma cells and macrophages, visualization of cancer 
cell aggregate distribution and precise measurement of 
cell–cell distances. The device consisted of 2 inner and 2 
outer channels. It was built in a way to allow the “contact 
condition” and “separated condition” circumstances ena-
bling macrophages to be positioned in a direct contact or 
separated from carcinoma cells aggregates. In details, the 
inner channels were filled with type I collagen gel solu-
tion in order to create a “contact condition”. One of the 
outer channels was devoted for HUVECs culturing and 
growing in EGM-2 endothelial cell growth media. The 
tumor cells and macrophages were subsequently intro-
duced into the inner channel that was the farthest from 
the previously described outer channel. Last outer chan-
nel was filled with DMEM that was changed on a 24-h 
cycle. In order to create a “separated condition” the mac-
rophages and tumor cells were introduced separately 
into different inner channels. Using this device, Bai et al. 
also demonstrated the distinct roles of macrophage sub-
types in the induction of the EMT phenotype of lung 
carcinoma cells. M1 and M2b macrophages were highly 
capable of inducing EMT, regardless of the studied 
conditions. Interestingly, M2a was established to possess 
the fastest and preferential migrated abilities toward car-
cinoma aggregates as well as to promote cells aggregate 
dispersion in greater majority in “contact” conditions. 
The greatest achievement of their study was to evidence 
the M2a promoting impact on carcinoma cells dissocia-
tion through a CD11b and ICAM-1 interaction.
Fibroblasts are the components of connective tis-
sue, however in cancer modified stroma they acquire an 
aggressive phenotype, named cancer-associated fibro-
blasts (CAFs), which demonstrate mesenchymal-like 
phenotypes and are capable of promotion of tumori-
genesis [82]. To address this issue, Yu et al. engineered a 
3D co-culture microfluidic system to emulate an in vitro 
tumor microenvironment [75]. The proposed device ena-
bles to investigate the interactions of cancer cells and 
various cellular components of stroma in real time. Their 
work aimed to elucidate the influence of CAFs on human 
lung adenocarcinoma progression. The ability of the 
device to create the in vivo microenvironment was exam-
ined by normal human fibroblasts activation to CAFs and 
measurement of myofibroblast markers concentration. 
In the subsequent steps the device provided the informa-
tion about enhanced NSCLS cells motility, promoted by 
CAFs-secreted components. The obtained results conjec-
tured that CAFs influence the progression in human lung 
carcinoma cells via increased expression of GRP78.
A significant role in tumor progression is played by 
transmembrane receptors. CD47 is the ligand for the 
receptors expressed on the macrophages and other 
phagocytic-like cells that inhibits macrophage phago-
cytosis causing the cancer metastasis propagation [47, 
83]. The overexpression of CD47 was reported in vari-
ous malignances and its contribution in the progression 
of NSCLC has recently been investigated by Zhao and 
collaborators [47]. They fabricated a microfluidic chip 
that served for the measurement of migration and inva-
sion of intact NSCLC cells, siRNA NSCLC and NSCLC 
cells with overexpression of CD47. The chip involved 
three microchannels and two rows with micro-gaps that 
permitted cells extravasation following the chemical 
gradient. The first utmost chamber served for cells seed-
ing, the inner chamber was filled with Matrigel and the 
last contained the chemoattractant FBS. Their results 
revealed that siRNA down-regulated the CD47 expres-
sion leading to suppression of cells’ migration/invasion, 
while overexpression of CD47 significantly enhanced 
cells’ migration and invasion abilities. Moreover, in vitro 
the results obtained in the chip and the in vivo obtained 
from on a mice model were consistent and indicated a 
metastasis inhibition by targeting CD47.
Still, many regulatory factors that promote metasta-
sis on a molecular level have remained undiscovered. 
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Recently, Guo et al. investigated the impact of the tran-
scription/translation factor Y-box-binding protein-1 
(YBX1) on NSCLC aggressiveness [74]. One of the stages 
of the experiment was the development of a microfluidic 
model for studying the YBX1 mediated lung cancer cells 
invasion. The aggressiveness of stimulated cells was indi-
cated by an increase in the invasive distance and area. 




Intra- and extravasation are the processes of cells trans-
migration into vasculature and out of vasculature, 
respectively. The first one gives rise to cells spreading 
through the vessels, and the second results in seeding the 
distinct localization by primary tumor cells. The move-
ment of tumor cells through endothelium is supported by 
the participation of neutrophils and  CB11b+. Neutrophils 
produce the matrix metalloproteinase-9 (MMP-9) [84], 
while dendritic cells  CB11b+ participate in directing of 
cancer cells toward distant sites in the organism. Moreo-
ver, the tumor cells’ closeness to the endothelial barrier 
[85] and expression of cytokines such as TGFβ augment 
the vessels permeability [62]. Cancer cells are also capa-
ble of secreting protein angiopoietin-like-4 (Angptl4), 
EREG, COX-2, MMP-1, and MMP-2 that may facilitate 
extravasation. Pulmonary hyper-permeability induc-
tion is associated with angiopoietin2 (Angpt2), MMP-3, 
MMP-10, placental growth factor, VEGF, and inflamma-
tory monocytes [59].
A significant meaning during cells intravasation and 
extravasation has the formation of invadopodia, that are 
able to penetrate the basement membrane via localiza-
tion of proteases and extracellular matrix degradation 
[9, 86]. There are many factors involved in invadopodia 
formation (e.g., EGF, matrix metalloproteases, PDGF, 
PKC, N-WASP, ERK), however the molecular mecha-
nism of their formation remains unclear [9]. Wang et al. 
engineered a microfluidic device for 3D culture to study 
the process of invadopodia formation by the human non-
small cell lung cancer cell line A549 [9]. Cells culturing 
in a 3D mode was aimed at mimicking the in vivo micro-
environment, thus the device was made from polydi-
methylsiloxane (PDMS) in order to provide a conducive 
condition for cell growth and proliferation. The fresh 
medium was constantly supplied at a control flow rate 
by an injection pump. An ECM microenvironment was 
obtained by Basement Membrane Extract (BME) sub-
stitution, since it contains ECM-like compounds. The 
device consisted of three units with a mutual outlet. Each 
unit possessed its own inlet for compounds application 
and medium addition. The construction of the device 
enabled the simultaneous performance of the analysis 
on three different studied groups: control group, EGF 
and GM6001/EGF groups. EGF was studied because of 
its stimulating properties for cell growth and cell motil-
ity, while GM6001 was used as a MMP inhibitor. The 
assessment of invadopodia formation of the cells was 
performed by detection of F-actin and cortactin expres-
sion by subsequent immunofluorescence. The invado-
podia morphology was inspected by confocal imaging 
system. The obtained results provide evidence that EGF 
induces A549 cancer cell invadopodia formation and can 
be greatly inhibited by GM6001. The microfluidic system 
devised by Wang et  al. enables the exploration of inva-
dopodia formation to facilitate the understanding of the 
invasion mechanisms in metastasis and discovery of anti-
invasion therapeutic methods.
Brain metastases are one of the common secondary 
sites caused by lung cancer dissemination [87]. For that 
reason, the understanding of the interaction between 
lung tumor cells and the brain microvasculature wall in 
the process of extravasation could be a critical step in the 
development of new drugs that could serve as inhibitors 
of this process. Therefore, Xu et  al. [72] replicated the 
biochemical and mechanical traits of inflammatory brain 
microvascular endothelial cells (BMECs) in a microde-
vice to investigate the regulatory mechanisms and pos-
sible signaling pathways of the rolling and adhesion 
behavior of lung tumor A549 cells. The recapitulation 
of inflammatory BMECs was achieved by stimulation 
with TNF-α and application of fluidic shear stress. Their 
results demonstrated that lung tumor cells’ interaction 
with inflamed endothelium and lesion place is the key 
point in the extravasation process, however this can be 
reversed after Rho/ROCK inhibitor administration.
Microfluidic platforms have also been used to study 
intra- and extravasation in relation to different cancers 
cells, such as the breast cancer-cell lines: MDA-MB-231 
[85, 88], colon cancer-cell line: LOVO and SW480 [89], 
and salivary gland adenoid cystic carcinoma-cell line: 
ACC-M [90]. Recent refinements in the microfluidic 
systems construction for a closer understanding of the 
mechanisms of intra- and extravasation were performed 
by Cui et al. [76] and Chen et al. [58]. Cui et al. proposed 
a microengineered device comprising multiple inde-
pendent chambers and a biocompatible porous mem-
brane for the selective gathering of the cells that migrate 
through endothelium [76]. The transendothelial migra-
tory capability of MDA-MB-231 cell line was observed 
under the circumstances of a defined shear stress and 
in sub-regions with the full coverage of endothelial 
layer. The results obtained from the experiment demon-
strated differences in body aspect ratio, planar migration, 
stress fiber alignment, and nuclear paladin expression 
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in comparison to cell with non-migratory phenotype. 
Interestingly, the device can be configured for other cells 
examination and has potential for biofluids like serum 
and whole blood investigation. An innovative approach 
concerning transendothelial migration was reported by 
Chen et al. [58]. They developed a microengineered sys-
tem with the capability of self-organized human micro-
vascular networks creation and an easy differentiation 
between extravasated, mid-extravasated and intravasa-
tion cells using standard confocal microscopy. The con-
struction of the device ensured the quantification of 
tumor cells kinetic data (protrusion initiation rate and 
speed of complete transmigration), fast imaging, and 
accurate extravasation scoring.
Neoangiogenesis
Microfluidic systems that imitate vascularisation for-
mation are restricted to a few cases [91] which mostly 
consider non-cancer-related matters [92–94]. However, 
neoangiogenesis is a key step in tumor development 
and metastasis. During this process new capillaries are 
formed allowing tumor cell growth by nutrients and 
oxygen delivery [88]. This process is signaling-depend-
ent [62] and involves the incorporation of pre-existing 
endothelial cells, the recruitment of progenitor cells from 
endothelium and transendothelial migration toward 
the metastatic place [95]. The surrounding environ-
ment undergoes stimulation by neoangiogenesis factors, 
however they do not have to be directly generated from 
tumor cells [62]. Examples of neoangiogenesis stimula-
tors are bFGF, VEGF, TGFβ-1, HGF, TNF-α, PDEGF, 
angiogenin [96, 97] and Il-8 [96, 98, 99]. These interac-
tions concerning signaling factors releasing, targeted cell 
migration and reorganization of the environment next 
to the metastatic place are strongly associated with cell 
communication. Heterotypic (cells of different type) cell-
to-cell interactions are observed between cancer cells as 
well as with the extracellular matrix during vasculogen-
esis. Vascularization can also occur in alternative ways by 
glomeruloid microvessel growth, vasculogenic mimicry, 
intussusceptive microvascular growth, postnatal vasculo-
genesis and vessel co-option [100].
The complexity of the vasculogenesis process was 
investigated by Alonzo et  al. who constructed a micro-
fluidic system for this purpose [91]. The results revealed 
that vessel network formation depends on interstitial 
flow mediated communication and stromal cells partici-
pation. The system enabled to study the interstitial flow 
influence on heterotypic and homotypic cell–cell interac-
tions on the vasculogenesis. Moreover, the device deliv-
ered an initial spatial and temporal pattern for studying 
the interactions between cells participating in vasculo-
genesis and the surrounding environment. The device 
also gives the possibility for microenvironments’ isola-
tion in the 3D model.
Cancer cells migration
Migration is a critical process of metastasis that pro-
claims the invasive phenotype of cancer cells [62]. It is a 
complex process that is extremely sensitive to extracel-
lular matrix and media stimulation [101]. Integrins, ion 
channels, cell adhesion molecules, soluble cytokines, 
growth factors, matrix-degrading proteases, and Rho 
GTPases [62, 79, 102] are the molecules that mediate 
cancer cells’ migration. Integrins are accountable for the 
transduction of mechanical signals from ECM into cells 
via focal adhesions and other macromolecular com-
plexes. The focal adhesions in turn may modulate cell 
motility by activation of kinases such as FAK and PI3K. 
PI3K thus may activate Rho that belongs to Rho family 
GTPases. The Rho activates ROCK that correlates with 
the promotion of tumor metastasis. Physical features of 
some focal adhesions such as shape and size may also 
influence the targeting of cell movement. Polymerization 
of actin cytoskeleton is another predictor of cell motility. 
Similarly does cofilin, one of the actin-binding molecules, 
that is also engaged in cell migration promotion under 
optimal expression [62].
There are three different types of migration modes: epi-
thelial (non-migratory), mesenchymal (migratory) and 
amoeboid known also as lobopodial (squeezing motility) 
[103], however the processes of mode switching have not 
been well explained. A microfluidic device that allows 
the investigation of the impact of different microenvi-
ronmental conditions on cancer cells migration mode 
and measure H1299 lung adenocarcinoma cancer cells’ 
motility by quantitative image analysis was proposed 
by Anguiano et al. [5]. Their chip has a central chamber 
serving as an inlet for loading of hydrogels and cells, and 
lateral channels for serum insertion. Microenvironments 
were recapitulated by the application of three types of 
hydrogels. One hydrogel contained pure collagen type I 
(C), and the next two were obtained by the fusion of col-
lagen type I and Matrigel (CM—1:1/collagen:Matrigel, 
CM+—1:2/collagen:Matrigel). Matrigel was recom-
mended for 3D culturing. It is a kind of a basement mem-
brane rich in fibrin, collagen and a number of growth 
factors that may serve as a microenvironment after can-
cer invasion [5, 104]. Researchers noticed that exposi-
tion to relatively more cross-linked environment (CM) 
resulted in faster cells migration coinciding with a display 
of the lobopodial phenotype. They explained this phe-
nomenon as an impact of environment rigidity, increased 
pore size, and appearance of soluble factors that activate 
the GTPase RhoA pathway. However, a further increase 
of hydrogel stiffness (CM+) resulted in movement 
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impairment. The changes in type switching from mesen-
chymal to amoeboid were explained by referring to the 
effectiveness of migration. The mesenchymal movement 
is more effective in smaller pore sized hydrogels, while 
amoeboid in higher pore sized hydrogels, which enhance 
the cell migration speed. Moreover, they noted that the 
Anti-β1 and Anti-β3 integrins blockage modulated the 
transition from mesenchymal to amoeboid [5].
Migration in metastasis is a directed cells’ move-
ment that can be guided by chemical and electrical cues. 
Chemical cues are generated by tissue-derived chemical 
factors, named chemoattractants that form a chemical/
biochemical concentration gradient [105]. Although, the 
biochemical gradients have been noticed to significantly 
influence the chemotactic cells’ response via cellular 
morphology and migration rate modification, or gene 
expression and signaling cascades regulation [78], the 
complexity of mechanisms involved needs deeper explo-
ration. To study this issue, Zou et al. constructed a micro-
fluidic network that generated multiple stable gradients 
for the examination of the chemotaxis related migratory 
responses of lung cancer stem cells (LCSC) and differen-
tiated lung cancer stem cells (dLCSC) [78]. This chip per-
mitted the observation of the migratory behavior of both 
LCSC and dLCSC in Wnt signaling pathway dependent 
of β-catenin in real time. The application of different gra-
dients induced different migration cell rates and different 
response of studied subcultures. Interestingly, dLCSC 
occurred to be more sensitive for gradient stimulation in 
comparison to LCSC. Moreover, the application of XAV-
939 resulted in inhibition of β-catenin signaling, leading 
to the suppression of chemotactic migration rates.
The influence of the EGF factor on cell movement in 
a microfluidic system engineered especially for this pur-
pose was investigated by Tata et al. [38]. The basic units 
were two chambers linked by ten microchannels. One 
chamber was dedicated for seeding of lung metastasized 
prostate cancer (PC3-ML) cells while the second for EGF 
introduction. Microchannels enabled the observation of 
cancer cell migration toward the attractant in a concen-
tration-dependent manner. The highest response in cell 
movement occurred after the application of 100 ng ml−1 
of EGF.
In recent years, increased interest has been directed 
to the impact of direct current electrical field (dcEF) on 
tumorigenesis. It has been reported that cell may undergo 
reorientation and migration in an electric field-induced 
manner. This phenomenon is called electrotaxis or galva-
notaxis [80]. Physiological values of dcEFs in the animal 
body occur from 50 to 500 mV mm−1 and are produced 
by transepithelial potentials [77, 106]. It has already been 
proven that the electric field is involved in embryonal 
development, wound healing, bone regeneration, and 
tumor metastasis [39, 105]. To address this issue in con-
text of metastasis, Huang et al. developed a microfluidic 
device for a long-term electrotaxis study of the human 
lung adenocarcinoma cell lines CL1-0 and CL1-5 under 
microscope monitoring [39]. The chip integrated a tightly 
sealed cell culture chamber and a heater with thermostat. 
The construction of the chip allowed the application of 
simultaneous multiple electric fields in a single experi-
ment. The experiment revealed differences between 
studied subcultures of carcinoma lung cells in response 
to electric fields stimulation. The CL1-5 cells considered 
as highly metastatic showed strong electrotactic response 
while no influence was observed on CL1-0 cells. Moreo-
ver, based on the CL1-5 cells specific movement after 1 h 
of stimulation, it was suggested that different signaling 
pathways may influence cells orientation and migration.
Li et al. constructed a microfluidic device for mimick-
ing the endogenous environment, where they applied 
dcEF for examination of the electrotactic migration of 
non-small cell lung cancer cell lines (H460, HCC827, 
H1299, and H1975) [80]. The experiment consisted of 
following steps: (i) glass slide coating with fibronec-
tin, (ii) cells introduction for culturing from 48  h up 
to 60  h, and (iii) placing electrodes into the medium 
channel and electrical stimulation. After accomplish-
ing the examination, a quantitative real-time PCR and 
quantitative analysis of cell migration were performed. 
The experiment enabled the study of different migra-
tion behaviors of cancer cells, as well as the observa-
tion of changes in dcEF-induced cell morphology and 
protrusion formation. The application of dcEF resulted 
in a migration of H460 and H1975 cells to cathode, 
while H1299 migrated toward anode. HCC827 had 
weak anodal directionality. Increased motility and 
cell reorientation were noted in H1299 and HCC827. 
Based on mRNA expression they revealed that MAPK 
and PI3K signaling pathways are associated with dcEF 
stimulation. Moreover, the relationship of dcEF stimu-
lation with  Ca2+ signaling in the migratory behavior of 
lung cancers cells was also reported. Obtained results 
proved once again the existence of intrinsic heteroge-
neity within the same cancer cell line. In later stages of 
their work, Li et al. proposed two microfluidic devices. 
The first was a more complex microfluidic system for 
long-term cells migration study under electric field, 
while the second was addressed to the isolation of sub-
populations based on different responses to electric 
field [79]. New devices maintained controllable micro-
environmental conditions and allowed cells’ motility 
observation in real time. The lung cancer cells H1975 
used in this study revealed cathodal migration. Fur-
thermore, their movement seemed to be dependent on 
the EF stimulation and specific genes expression. The 
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motility of studying cell lines under EF stimulation was 
related to phosphatidylinositol-3,4,5-trisphosphate 
3-phosphatase (PTEN) expression, while the absence 
of EF was associated with EGFR expression. The inves-
tigation enabled to establish that upregulation of RhoA 
was linked to high cells motility. The second chip 
allowed the isolation of the cellular subpopulations 
with different electric induced migration abilities.
An interesting approach was presented by Hou et al., 
who proposed a multi-conditional microengineered 
system for simultaneous chemotactical and electro-
tactical cell stimulation for molecular mechanism 
exploration [106]. This chip integrated several isolated 
channels with a single chemical circuit and isolated 
chemical flow. This approach enabled to establish that 
the ROCK inhibitor influenced specific suppression of 
the directedness of CL1-5 cells movement. Moreover, 
the addition of the PI3K inhibitor resulted in the sup-
pression of both the directedness and migration speed 
of cells toward anode. The influence of the ROCK 
blocker on the morphology of studied cells was also 
reported. ROCK was suggested to play a greater role 
in directing anodic motility under the electric field. 
In subsequent studies, Hou and collaborators [107] 
proposed a multichannel dual-electric-field (MDF) 
chip that permitted to simultaneously culture differ-
ent types of cells in one experiment or simultaneously 
testing different chemical factors that may influence 
the electrotaxis.
Employment of dcEF for chemotactical CL1-5 cells 
modulation in a microfluidic cell culture chip was 
also performed by Kao et  al. [77]. The results dem-
onstrated that dcEF stimulation in the range of 180–
540  mV  mm−1 resulted in anode-directed migration 
of CL1-5 cells. Moreover, they postulated that EGF 
stimulation resulted in directional motion while dcEF 
stimulation gave rise to speed acceleration and direc-
tion of cells movement.
Circulating tumor cells
Circulating tumor cells (CTCs) disseminate from the pri-
mary tumor. They intravasate into the circulatory system 
to travel to distant parts of the body organs in order to 
form the secondary tumor-metastatic disease [108]. The 
number of released tumor cells is unknown, however 
experimental data indicate that their number is extremely 
low, such as one CTC per million leukocytes [109] and 
one CTC per billion erythrocytes [110]. Moreover, they 
are highly heterogeneous and therefore may exhibit dif-
ferent phenotypes. Their properties may quickly evolve 
[111] contributing to difficulties in CTC isolation from 
whole blood. CTCs may also form CTCs aggregates that 
may provide valuable information about the nature of 
cancer metastasis. These are considered to be even 100-
fold more metastatic in comparison to single CTCs [112].
The attempts of CTCs enrichment and isolation using 
microfluidic devices have been many times reviewed. 
Most of the microfluidic devices are constructed based 
on the biochemical and biophysical properties of CTCs. 
The biochemical properties of cells are used in affinity-
based techniques. These techniques focus on the specific 
bonding between antigens expressed on the surface of 
cells and molecules fasten to various microstructures in 
the microfluidic system. Separation based on biophysi-
cal properties, named label-free isolation, mainly con-
cerns the differences in size between CTCs and other 
components of blood, however, new size-independent 
approaches for electrical properties determination have 
been lately reported. In literature, we can even find the 
combination of aforementioned techniques [113]. Espe-
cially sensitive methods are necessary for CTC clusters 
isolation as they may detach into single cells or smaller 
aggregates. Hence, to preserve their integrity, isolation by 
size and asymmetry with application of low shear stress 
conditions were proposed [112, 114]. The advantages and 
disadvantages of both isolation techniques are summa-
rized in Table 1 [42, 115, 116].
Table 1 Advantages and disadvantages of affinity-based and label-free isolation [17, 117, 118]
Advantages Disadvantages
Affinity‑based isolation Highly specific
High purity of CTCs
Application of the combination of antibodies allow to capture cells with epithe‑
lial and mesenchymal phenotype
Capture of CTC clusters
Separation/categorization based on abundance of Ep‑CAM expression
Limitations in velocity and flow
Blood volume
Decrease of cell viability during the 
detachment process
High cost of antibodies
Low capture efficiency
Label‑free isolation High‑throughput
Allow CTCs capture regardless of subpopulation differences and EMT process
Allow further cell molecular characterization
Allow cell culturing and further recovery in suspension
Allow preservation of cell clusters to study their metastatic ability
Low cost
Capture depends on size pores
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Affinity‑based techniques
Affinity-based techniques depend on highly specific reac-
tion between cells’ surface specific antigens and ligands 
immobilized in the microfluidic device. The majority of 
the affinity-based methods utilize positive capture, i.e., 
trapping of CTCs via EpCAM—a transmembrane gly-
coprotein expressed on cancer cells’ surface [119]. The 
binding between EpCAM and the anti-EpCAM antibody 
coated on the microdevice channels is highly specific, 
however only enables to capture the CTCs that pos-
sess epithelial phenotype [120]. Such an approach is not 
appropriate for CTCs isolation that undergo an EMT 
process or express mesenchymal phenotype [121, 122]. 
More comprehensive applications exploit antibodies 
against the leucocyte antigen CD45 [123], called nega-
tive separation. This approach allows the isolation of all 
types of CTCs regardless of their phenotype. The appli-
cation of antibodies against specific antigens toward par-
ticular cancers were also reported [115]. For example, 
anti-tyrosine-protein kinase receptor (anti-HER2) was 
employed for recognition of HER2 positive breast can-
cer [124]. An antibody for prostate-specific membrane 
antigen (PSMA) was used for prostate cancer circulating 
tumor cells entrapment [125]. Anti-podoplanin, an anti-
body against malignant pleural mesothelioma was also 
successfully used instead of anti-EpCAM [126].
Recently, aptamers, the single-stranded oligonucleo-
tides (RNA and DNA), that possess the ability to spe-
cifically bind to proteins, ions or small molecules have 
drawn the attention to microfluidic systems construc-
tors [127]. Aptamers are considered as better surrogates 
than antibodies as they are able to recognize more sub-
tle features and low-immunogenic molecules of CTCs. 
The major advantages of aptamers are their high speci-
ficity and wide range of application regardless of specific 
knowledge about targeted molecule expression on the 
CTCs surface [128]. Recognition peptides are other link-
ers also acknowledged as adequate antibody substitutes 
for CTCs capture. This is due to their application simplic-
ity and employment in ligand-receptor and protein–pro-
tein interactions [129].
The development of affinity-based techniques results 
in the improvement of the efficiency of CTCs separa-
tion from other components of blood and creation of 
the opportunity for cells segregation based on the abun-
dance of surface markers expression [117, 130, 131]. This 
progress is possible among others through magnetic 
affinity-selection achieved by magnetic ranking cytom-
etry (MagRC) [111, 132] and employment of magnetic 
items such as beads [17, 131, 133] and nanoparticles [17, 
117, 130, 134, 135] coated with antibodies [131, 134], 
aptamers [17, 130] and peptides [121]. Employment of 
magnetic items permits the purification achievement 
by target cells gathering via a magnetic field [17], or by 
application of a magnetic sorter [131]. Magnetic ranking 
cytometry performs a nanoparticle mediated cells sorting 
in different zones according to their phenotypic ranking. 
The isolation undergoes through the binding of antibody-
functionalized magnetic nanoparticles to surface expres-
sion markers of CTCs and subsequent cell separation 
according to a magnetic field gradient [111, 132]. How-
ever, recently, magnetic nanoparticles were also found to 
be employed for different CTCs subpopulation trapping 
[115].
The enhancement of capture efficacy can also be 
obtained by Fc-domain EpCAM antibody modification 
[120]. The capture yield can be increased by antibodies’ 
immobilization at various nanostructures such as nano-
pillars [15], nanofibers [136], nanorods [137] or nanow-
ires [135]. They were reported to be composed or covered 
with gold nanoparticles [138], graphene oxide [122], or 
 TiO2 [137] as they were accounted to augment the cells’ 
immobilization on various surfaces and enhance the cells’ 
capture. Carbon nanotubes [18] have also been used. The 
attempt of microbubbles decoration with EpCAM was 
also reported [139]. Equipment containing microfluidic 
chips with additional supporting units like multi-vortex 
mixing module [17] or X-shaped low flow regions [117] 
for increase of the effective binding were also notified.
Currently, microfluidic chips constructors endeavor to 
integrate all steps necessary for cells isolation, enrich-
ment and detection into one chip. An example of such a 
device is the microfluidic system designed by Tsai et  al. 
[17] that comprises RBC lysis, WBC depletion and CTC 
isolation. An interesting approach of CTC enrichment 
was proposed by Jiang et  al. [118], whose microfluidic 
platform allowed the purification by sequential elimina-
tion of unwanted blood components by application of 
deterministic lateral displacement (DLD) and by auto-
matic immunomagnetic purification [118].
Label‑free techniques
The advantage of label-free separation methods rely on 
the ability to isolate CTCs regardless of their surface 
markers, but with regard to cancer cells size [140, 141], 
fluid viscosity, cell density [113] and electrical proper-
ties [43, 142]. In the majority of label-free devices, the 
enrichment is achieved based on differences in physical 
properties between cancer cells and the other compo-
nents of blood. The microfluidic methods developed for 
this purpose include a membrane-based separation [110], 
dielectrophoresis [143, 144], acustophoresis [113], and 
hydrodynamic-based separations [145]. Size-independ-
ent techniques like impedimetric separation are the latest 
achievements in the field of microfluidic systems pro-
gression [43, 142].
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Membrane-based separation or filters employment 
depends on pores, gaps and microcavity array occur-
rence in devices’ construction. The membranes or filters 
possess pore/gap sizes from 5 µm up to 11 µm [115, 146], 
which were selected taking into account the cancer cells’ 
sizes and deformability. It was estimated that CTCs sizes 
are in the range of 10–20 µm, while red blood cells and 
leukocytes around 4–8.5  µm [116, 147] and 6–20  µm 
[116], respectively. However, CTCs from patients with 
non-small cell lung cancer were found to have a diameter 
range of 15–25 µm [148]. To separate cells with satisfac-
tory efficiency the separation membrane should be made 
from appropriate materials. Membranes with suitable 
surface area, porosity and with satisfactory cell detach-
ment were found to be created from polycarbonate [149, 
150], parylene-C [151] and Mg-embedded parylene-C 
[152]. A membrane-based separation can be achieved 
among others by a double spiral microchannel applica-
tion that hydrodynamically separates large CTCs from 
small blood cells [110] or centrifugal force application 
[150, 153]. Filters can be equipped with microcapillary 
arrays that may separate cells by deterministic lateral dis-
placement. The significant impact on cells’ separation has 
also an assortment of appropriate flow rates. Low flow 
rates can lead to sample deterioration, however too high 
usually results in insufficient cell capturing as a result of 
passing through the microcavities [147, 154]. The flow 
rate cannot be clearly defined, its value depends on the 
shapes, sizes and microchannels geometry [155, 156]. 
Moreover, the flow rate may generate shear stresses and if 
these are high they may induce CTCs necrosis [157].
Hydrodynamic-based separations were recognized as 
highly throughput approaches. Currently, there is a sig-
nificant number of microfluidic devices that were created 
based on hydrodynamic effects. They utilize the inertial 
fluid dynamic effects [16, 145], the Dean flow that occurs 
in spiral separators [110, 148, 158, 159], hydrophoresis 
[160], parallel multi-orifice flow fractionation (p-MOFF) 
[161], deterministic lateral displacement [162], and iner-
tial separation [163].
The acustophoresis aims at cell specific lateral dis-
placement based on cells’ acoustic mobility [164]. The 
separation is performed by a horizontal and vertical pre-
alignment of the cells suspended in a sample by ultra-
sound. It allows cells’ location in a regular flow velocity 
regime within a parabolic flow profile [165]. This method 
enables cells’ differentiation based on their size, density, 
compressibility, or a combination thereof [166].
Dielectrophoresis allows to control cells’ movement 
in non-uniform electric fields based on their polariza-
tion and induction of a dipole moment [143, 167]. Wire 
electrodes are used to obtain the  electric field, however 
recent reports suggest a more effective usage of arrays 
of wireless bipolar electrodes, since this overcomes cells’ 
capture and clogging in the channels and enables simul-
taneous entrapment across the parallel channels [168]. 
Recently, new microfluidic chips with optically induced 
dielectrophoresis were developed. The principle of 
the method is based on a uniform electric field genera-
tion for electrical polarization of microparticles. Subse-
quently, the light illumination of a photoconductive layer 
results in the generation of a non-uniform electric field. 
The interaction between the polarized electrical field 
and non-uniform electric field allows for microparticles’ 
manipulation for CTCs isolation from leukocytes based 
on the differences in their sizes [144, 169, 170]. Such 
methods are considered favorable for point-of-care appli-
cations [171].
In recent times, size-independent techniques that allow 
CTCs and their subpopulation (epithelial- and mesen-
chymal CTCs) isolation using impedance [43, 142] were 
developed (Fig. 4). A device named nanoelectromechani-
cal CTC Chip (NELMEC) was created for electrical sig-
nal measurement in order to distinguish entrapped cells 
(CTCs from large leucocytes) based on the differences 
in membrane capacitance [43]. Erythrocytes, platelets 
and small leucocytes freely pass through the channels 
and the cells’ entrapment takes place at the junction 
between microchannels and channels, where silicon 
nanograss (SiNG) electrodes are localized, which enable 
a direct electric signal measurement from captured cells. 
Another type of device is represented by the low-sample-
loss microfluidic system that enables the characterization 
of CTCs’ electrical properties by measuring the specific 
membrane capacitance and cytoplasm conductivity [142]. 
The cellular electrical properties are measured using sil-
ver electrodes and a lock-in amplifier. An electrochemi-
cal impedimetric biosensor employed with multi-walled 
carbon nanotubes (MWCNTs) for CTCs detection was 
also constructed [18]. EpCAM antibodies were linked to 
MWCNTs which were assembled on indium tin oxide 
(ITO) glass, allowing an effective capture of cells on the 
electrode surface via binding with cell surface EpCAM. 
Impedance-based microfluidic flow cytometry (IBMFC) 
is also worth noting for CTCs identification [172]. As an 
example, the IBMFC can integrate a printed circuit board 
and a reusable pre-deposited copper electrode. Changes 
in the impedance signal between the electrodes carry the 
information about cell density, shape and morphological 
parameters.
Label-free CTCs separation usually needs further cel-
lular refinement with immunostaining for CTC and 
leukocyte recognition [173], or gene identification by 
RNA-sequencing, qRT-PCR [174] or flow-cytometry 
[148] for quantification. This requires larger equip-
ment and staff specialized in electronics, however these 
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inconveniences are currently being addressed. A micro-
chip that integrates optics for fluorescence quantifica-
tion of CTCs has been described and the results obtained 
using the optofluidic device were consistent with those 
obtained from flow-cytometry, conventional imaging and 
serological tests [124].
CTCs isolation from lung cancer metastasis patients
Several microfluidic systems have already been employed 
for lung metastasis screening of CTCs (Tables 2 and 3). 
They utilize anti-EpCAM antibody conjugation to mag-
netic upconversion of nanoparticles for CTCs capture 
[109], as well as anti-EpCAM substitution with A-1 pep-
tide for different types of CTCs entrapment including 
those undergoing EMT process [121]. Parallel pre-EMT 
and post-EMT cells capture was also proven possi-
ble using nanoroughened glass [173]. This microfluidic 
platform for CTCs capture comprises two functional 
components: (i) a nanoroughened glass substrate with 
nanoscale topological structures to enhance adher-
ent interactions between the glass substrate and cancer 
cells, and (ii) an overlaid PDMS chip with a low profile 
microfluidic capture chamber that promotes CTC-sub-
strate contact frequency [173]. Immunostaining with 
cytokeratin-fluorescein isothiocyanate (FITC) for epithe-
lial CTC [148], CD45- phycoerythrin (PE) for leukocyte 
[175], APC-conjugated anti-CD45 antibodies [148], and 
DAPI for nucleus [175], with Hoechst for DNA [148] can 
be be additionally employed. Usually the identification of 
CTCs is frequently associated with further refinement, 
e.g., by combination with genomic DNA extraction for 
mutational analysis of EGFR [176], with next generation 
sequencing [177], FISH assay application for identifica-
tion of genomic alterations and mass spectrometry for 
mutational profiling [158] or loop-mediated isothermal 
amplification (LAMP) for detection of CK-19 mRNA 
from captured CTCs [110].
Organ on a chip
A continuous improvement and development of more 
and more sophisticated microfluidic systems is tak-
ing place in order to enhance the capacity to investigate 
highly complicated processes such a metastasis. Sys-
tems such as “organ on a chip” [181–183], “cancer on a 
chip” [184–186], and “metastasis on a chip” [187] etc. are 
among the latest achievements regarding biomimetics 
with regard to the functioning of living organs and pro-
viding appropriate conditions for studying the complex 
metastasis mechanisms. Employment of the dynamic 
microenvironment comprising multiple “organs”, vascu-
lature network and CTCs in one chip allows the tracing 
and measurement of the metastatic potential of cancer 
cells [44].
Breathing lung-on-a-chip was engineered by Huh 
et al. [188]. This microdevice is composed of two super-
imposed flow-through microfluidic channels separated 
by a microporous membrane. The upper chamber (ven-
tilation) supports the growth of human lung alveolar 
Fig. 4 Impedance measurements of adenocarcinomic human alveolar basal epithelial cells (A549) in the microfluidic device originally designed in 
the “GEMNS” project (EuroNanoMed II program) by the Nanotoxicology group at the University of Bergen, Norway. Please see video information for 
A549 cells in the microfluidic device set‑up (Additional file 1)
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epithelial cells, while the lower chamber (perfusion) is 
lined with lung microvascular endothelial cells facing 
a constant flow of fluid to mimic the blood stream. To 
recapitulate the mechanical strain imposed by breath-
ing movements, the cell culture chamber is flanked by 
two hollow microchannels trough which cyclic suction 
is applied causing expansion and relaxation of the mem-
brane. This device could support the growth of micro-
tumors derived from lung cancer cells to study cancer 
cell migration and therapeutic efficacy of aerosolized or 
infused nanotherapeutics. Microelectrodes can be also 
implemented to monitor in real-time transepithelial 
electrical resistance. This model offers the opportunity 
to study cancer cell migration under physiologically rel-
evant conditions in  vitro, which includes a multicellu-
lar context, as well as biochemical and mechanical cues 
(breathing motion and fluid perfusion). For instance, 
microtumors derived from lung cancer cells can be devel-
oped within the ventilation chamber to then study cancer 
cell migration and invasion of the endothelial barrier. The 
process of invasion can be monitored in real-time and in 
a label-free manner by using transendothelial electrical 
resistance. Microelectrode arrays could be also fabricated 
in one side of the microporous membrane to study in 
closer detail the process of invasion via electrical imped-
ance spectroscopy. This model can not only be used to 
study the process of invasion, but also to test efficacy and 
possible side effects of novel chemotherapeutic agents 
administered as aerosols through the ventilation cham-
ber or in solution via the perfusion chamber [188].
Xu et  al. [189] have engineered a multi-organ micro-
fluidic chip for replicating the complex lung and dis-
tant organs interactions. The device consisted of one 
upstream chamber devoted to lung imitation and 3 
downstream chambers for brain, bone and liver reca-
pitulation. The replication of the selected organs was 
achieved by bronchial epithelial, astrocytes, osteoblasts 
and hepatocytes seeding. The invasiveness of lung cancer 
cells was verified by measurement of RANKL for bone-
specific metastasis, CXCR4 expression for brain-specific 
metastasis, and AFP for liver cell damage. The reliability 
of the results obtained from the application of a micro-
engineered platform was confirmed by comparison with 
an in vivo model. The results obtained indicated that the 
proposed organ on chip model can be used for effective 
recapitulation of lung cancer cells’ metastasis to distant 
organs.
The utility of biomimetic microsystems for assessment 
of the metastatic potential of various cancers to lung 
metastasis was also demonstrated by Kong et al. [44]. The 
device allowed the modeling of the potential of breast 
and salivary gland cancer cells to metastasize lung, liver 
Table 3 Summary of analytical performance of microfluidic devices applied to screen the sample spiked with lung cancer 
CTCs
SiNW silicon nanowire array, MUNPs multifunctional magnetic upconversion nanoparticles
Tumor type Microfluidic device Efficiency/capture rate Additional tests Refs.
A549 CTC‑Chip (affinity‑based) 87–100% Immunofluorescence cell staining with 
CK7/8 or TTF‑1 or Ki67 as well as the cor‑
responding secondary antibodies. After 
FACS sorting, CTCs were stained with EGFR 
and pan‑CK. CTCs also underwent RNA 
extraction, RT‑PCR, TP53 sequencing and 
next‑generation sequencing
[177]
A549 CTC‑Chip (affinity‑based) 60% Cells were immunofluorescence (IF) stained 
for Cytokeratin 7/8 (green), white blood 
cells were stained for CD45 (red) and 
nuclei were counterstained with DAPI
[177]
A549 Microfluidic SiNW with MUNPs conjugated 
with anti‑EpCAM
About 80% Cells were stained with the method of 
immuno‑fluorescence and then imaged 
under the confocal fluorescence micro‑
scope
[109]
A549 A‑1 peptide modified microfluidic chip 
(affinity‑based)
E‑A549 (58.0 ± 19.7%)
M‑A549 similar to E‑A549
The authors did not perform any additional 
tests
[121]
A549 and MDA‑MB‑231 Nanoroughened adhesion‑based capture 
of CTCs
> 80% CTCs were identified by: positive staining 
of anti‑cytokeratin and DAPI; negative 
staining of anti‑CD45; and appropriate 
morphometric characteristics including 
cell size, shape, and nuclear size
[173]
A549 Inertial‐based microfluidic cell sorter 74.4% Loop‑mediated isothermal amplification 
(LAMP) for detection of CK‑19 mRNA from 
captured CTCs
[110]
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and bone marrow (muscle cells were used as a control). 
The results from clinical observations and the results 
from mentioned studies were found to be consistent, as 
the metastatic potential to lung, liver and bone marrow 
was significantly higher than to muscle cells. Simultane-
ously, they performed an in  vivo study concerning lung 
metastasis on a nude mouse model. The obtained results 
from both studies revealed similar outcomes.
Besides “multi-organs” platforms that directly concern 
lung metastasis [189] or metastasis from lung [44], a type 
of platform called “metastasis on a chip” [187] should be 
noted. This was employed for the study of cells’ dissemi-
nation from colon carcinoma and their liver invasion and 
is not as advanced as the platforms aforedescribed, as 
it only possesses the possibility to study the interaction 
between two distinct tissues in the metastatic process.
The tumor microvasculature model by Sobrino et  al. 
[190] offers unique opportunities to study the processes 
of extravasation, intravasation and metastatic coloniza-
tion for the formation of secondary tumors from lung 
CTCs (Fig.  5). This model relies on the development of 
fully perfusable microvasculature accompanying 3D 
microtumors embedded in ECM gels. Because these 
microvessels are perfusable, drug screening for can-
cer treatment can be seamlessly achieved in large-scale 
setups. The information obtained with this model can be 
used to develop new drugs that can more easily cross the 
endothelial barrier and the intricated ECM to effectively 
reach and act on the microtumors under hypoxic condi-
tions. This model can be also used to study CTC extrava-
sation for the design of drugs that block this process.
Besides metastasis investigation, attempts have been 
made for cancers’ recapitulation. One of the proposi-
tion is “tumor tissue-on-a-chip” developed by Astolfi 
et al. that used tumor cells directly obtained from biopsy 
or surgery [186]. The microfluidic chip had the poten-
tial of parallel screening of several drugs. It involved five 
microchannels with sedimentation trap for collecting 
the micro-dissected tumor/tissue samples (MDTs) from 
the specimen. The microchip permitted cells’ gathering 
in a constant number in each well with further submis-
sion to five different drug screening. The device proved to 
be suitable for the culturing of MDT cells from different 
types of patient tissues for several days and subsequent 
simultaneous cells’ observation after drug treatment. The 
usage of patient’s own cells for appropriate treatment 
selection could be an excellent solution for personalized 
treatment.
The whole human organs recapitulation on one min-
iaturized device is extremely important with regards 
to overcoming the shortcomings that arise from the 
imperfections and restrictions in application of in  vivo, 
2D and tissue 3D models [60]. The microfluidic-based 
organ-on-a-chip have numerous advantages, especially 
over static 2D models which provoke changes in cells 
morphology, their function and signaling preventing the 
cellular incorporation in a tumor structural conforma-
tion [191] and reproduction of the processes of tumori-
genesis and metastasis. In 2D culture, cells are organized 
in a monolayer while in studies upon carcinogenesis and 
metastasis the formation of a multilayer tumor mass 
is fundamental for the recapitulation of intracellular 
crosstalk between cancer cells and ECM for subsequent 
initiations of cancer cells dissemination, migration and 
metastatic niche organization. Organ-on-a-chip in com-
parison to static models create the opportunity for dif-
ferent cell types interactions [44, 192] under controllable 
fluid and nutrients transfer imitating in vivo conditions. 
Moreover, the microfluidic chip can be a powerful tool to 
study of the effectiveness and toxicity of new therapeu-
tics, which has many advantages over animal models, 
such as simplicity of use, time-saving and obtainment of 
fast results [192, 193]. Further improvements could result 
in diminishing the number of animals for testing and 
accelerate new drugs investigations [44].
Fig. 5 On‑chip biomimetic model to study metastatic lung cancer. 
Tumor microvasculature‑on‑a‑chip. Top‑view (top) and cross 
section (bottom) of a multicompartment microfluidic chip for the 
development of perfusable microvascular networks and microtumors. 
Diamond‑like chambers support the growth of microvascular 
networks emended in extracellular matrix (ECM) gels, while flanking 
side channels are used to perfused nutrients and drugs. Perfusable 
microvascular networks are formed by co‑culturing microvascular 
endothelial cells with lung fibroblast and vascular smooth muscle 
cells in the ECM gel. Lung cancer cells can be co‑injected before ECM 
gelification to grow microtumors. Alternatively, lung cancer cells can 
be perfused via flanking channels to study metastatic colonization 
(adapted from Sobrino et al. [190])
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Theranostics and anti-cancer drug testing
Advances in the development of microfluidic systems 
enables the insightful analysis of molecular mecha-
nisms of pathological processes and simultaneous novel 
therapeutic strategies implementation. The microfluidic 
devices have the ability to mimic the in  vivo environ-
ment, which may be particularly significant during drugs 
testing, since over 90% of antitumor therapeutic agents 
with successful pre-clinical trials fail during human clini-
cal testing [1, 194].
The rapid development in the field of microdevice 
engineering is evident, however most of the published 
research with usage of microfluidic devices is restricted 
to study of cells’ response to conventional chemothera-
peutics, such as cisplatin, doxorubicin or paclitaxel. Con-
ventional drugs generally have poor aqueous solubility, 
low bioavailability, insufficiency of selectivity toward can-
cerous cells and multidrug resistance [195]. In response 
to restrictions associated with conventional drug treat-
ment, scientists undertook the challenge of breakthrough 
nanoparticles development that may act as therapeutics 
and diagnostic agents. The combination of high-through-
put microfluidic devices with the possibility of testing 
multifunctional and precise theranostics will contribute 
to speeding up the time from development to implemen-
tation of new medicines and nanomedicines.
The development of nanotechnology provides the pos-
sibility to develop multifunctional nanostructures, aimed 
to be smart drug-delivery systems that combine the diag-
nostic and therapeutic features, called theranostics. The 
theranostic term was originally introduced by Funk-
houser in 2002 [196]. Lately, much attention has been 
devoted to the development of nanoparticles for thera-
nostics and to improvement of their properties, since 
they possess the potential for preferential drug delivery 
to cancer site and treatment monitoring [197]. One of 
the aims of theranostics is to augment the specificity of 
cancer treatment, forcing scientists to focus on targeted 
nanoparticles development. A wide range of potential 
theranostics has been reported including polymers [198], 
micelles [199], liposomes [200], quantum dots [201] and 
upconversion nanoparticles in their composition [202].
Microchips in conventional chemotherapeutics testing
A wide array of microfluidic devices for high through-
put drug screening have been reported [203]. Some of 
them have been used to test the effect of chemotherapeu-
tics on various lung cancers. Zhao et al. constructed the 
microfluidic chip to investigate the impact of verapamil 
on P-glycoprotein (P-gp) expression [204] using immu-
nofluorescence. Note that P-gp is responsible for dimin-
ishing the intracellular concentration of a broad range of 
cytotoxic agents, therefore resistance to the anticancer 
drug VP-16 after pretreatment of the human lung cancer 
cell line SPCA1 with verapamil or without was examined. 
The result suggested that verapamil could inhibit the 
P-gp expression contributing to enhancing the apoptosis 
induced by VP-16. The results were consistent with those 
obtained by flow cytometry.
One of the microfluidic device application in antican-
cer drug screening was demonstrated by Gao et al. [205]. 
They constructed a microfluidic system using photo-
lithography which had HepG2 and A549 cells encap-
sulated in hydrogel microstructures, immobilized in 
microfluidic channels. The cytotoxicity assessed by meas-
uring the level of intracellular glutathione (GSH) and of 
reactive oxygen species (ROS) in response to several con-
centrations of actinomycin D (Act D) and methotrexate 
(MTX). The presence of GSH and ROS was confirmed by 
fluorescence microscopy using labeling with 2,3-naph-
thalenedicarboxaldehyde (NDA) and dihydroethidium 
(DHE), respectively. The microfluidic system appeared 
to be a good replacement of traditional cells culturing in 
96-well plate.
Xu et  al. designed a microfluidic 3D co-culture drug 
sensitivity test platform [206] that aimed to construct 
an in  vivo-like tumor environment to assess anti-can-
cer drug efficacy. The designed microfluidic system was 
equipped with four microfluidic units for simultaneous 
examination of four different cell cultures and five injec-
tion pump for flow rate monitoring. Each microfluidic 
unit consisted of three chambers for cell culturing, two 
inputs for drug introduction and fresh medium supply, 
and a concentration gradient generator for mixing of 
the content from both inlets. The drug sensitivity assay 
was performed on non-small the cell lung cancer cell 
line (SPCA-1) exposed to chemotherapy drugs: gefitinib, 
paclitaxel (PTX), and gemcitabine (GCB). The cyto-
toxicity of the studied chemotherapeutics was assessed 
with the methylthiazolyl-diphenyl-tetrazolium bromide 
(MTT) test. The microfluidic device occurred to be useful 
for the combined drug screening. Moreover, the results 
demonstrated the extreme significance of tumor stroma 
on drug efficacy, since the apoptosis rate in response 
of anticancer drug testing in SPCA-1 cells co-cultured 
with stromal cells diminished approximately two times 
in comparison with monoculture of SPCA-1 cells. The 
researchers also performed an individualized treatment 
on primary cells prepared directly from the fresh lung 
cancer tissues gained from patients. The results obtained 
on cells from fresh tissue differed from those obtained 
from cancer cell lines.
Another interesting approach for anticancer drug 
testing was presented by Dereli-Korkut et  al. who con-
structed 3D microfluidic cell arrays for ex  vivo drug 
screening with mimicked vascular flow [207]. The 
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microengineered device had a three-layers construction 
for blood microvessels stimulation with an upper layer, 
permeable membrane with clustered pores in middle 
layer and 3D cell culturing in extracellular matrix in bot-
tom layer. The experiment was carried out with usage of 
human ductal breast epithelial tumor cell line (T47D), 
human non-small cell lung cancer cell line (PC9), and 
adult human dermal blood microvascular endothelial 
cells (HMVEC) encapsulated in viscous liquid form of 
PuraMatrix hydrogel. The impact of apoptotic inducers 
such as tarceva, staurosporine, TNF-α, and colchicines 
on caspase-3 activities of PC9 cells was tested in con-
ventional culture dishes and in the 3D microfluidic chip. 
Application of tarceva, staurosporine, and TNF-α with 
cycloheximide resulted in a fast increase of active cas-
pase-3 in PC9 cells in a 12 h test, while colchicine stim-
ulation gave greatly lower and slower response in time. 
Interestingly, at 17  h the highest caspase-3 activity was 
observed after staurosporine treatments. Beside this, the 
dynamic caspase-3 activity obtained from traditional 2D 
and microfluidic 3D testing were very different what may 
result from the absence of real circumstances prevailing 
in living organisms like shear stress applied by flow gen-
eration and waste products draining applied in microflu-
idic 3D chip.
A platform for mimicking organ-specific metastasis 
engineered by Kong et al. [44] was used for the anti-meta-
static reagent AMD3100 testing in lung metastasis. In the 
study, AMD3100 had an inhibitory effect on CXCR12—
chemokine supporting lung metastasis. Increasing 
concentrations of AMD3100 caused the reduction of pri-
mary lung cells and greatly inhibited lung metastasis of 
MDA-MB-231 cells in nude mice.
In another study, the impact of CAFs derived HGF 
on Met, PI3K and AKT phosphorylation, paclitaxel-
induced apoptosis and glucose-regulated protein 78 
(GRP78) expression in A549 cells was examined using of 
3D microfluidic chip fabricated by Ying et al. [208]. The 
device consisted of two layers. The upper layer involved 
two inlets for medium and drug solution perfusion. The 
lower layer had an input for drug introduction, four par-
allel chambers for cells culturing and linear concentration 
gradient generator for diffusive mixing. Normal fibro-
blasts transformed to CAFs after exposition to A549 cells 
and HGF production by CAFs was evidenced. Moreo-
ver, CAFs occurred to up-regulated anti-phosphorylated 
Met, PI3K, AKT and anti-GRP78 activation which was 
subsequently abrogated by addition of human HGF neu-
tralizing antibody. The treatment with paclitaxel revealed 
significantly lower A549 cell apoptosis when cells were 
maintained in a medium with CAFs than in non CAFs 
containing medium. Additionally, A549 cell apoptosis 
augmented during treatment with the inhibitor for PI3K 
or GRP78. All in all, the data obtained by researchers 
indicated that parallel inhibition of the PI3K and GRP78 
improved lung cancer A549 cells apoptosis effect induced 
by paclitaxel.
Microfluidics for nanosafety studies
Microfluidics for toxicological and therapeutic testing 
of nanomaterials
Traditional in  vitro cell-based assays cannot accurately 
reflect the in  vivo situation because they are commonly 
performed under non-physiologically relevant condi-
tions. For example, traditional toxicological and thera-
peutic assays are performed under static conditions, 
which do not offer adequate control over cell exposure 
to nanomaterials (NM)s; i.e., agglomeration/aggregation, 
sedimentation and buoyancy, which impact the number 
and size of nanoparticles and their eventual agglomer-
ates/aggregates that come in contact with cells [209]. 
In addition, static systems lack the dynamic microenvi-
ronment to which cells are exposed in in  vivo systems. 
Within tissues, continuous perfusion of interstitial fluid 
provides fresh nutrients to cells and removes waste mate-
rials. This continuous fluid flow might impact the amount 
of NMs internalized by cells [210] (Fig. 6). Furthermore, 
conventional in vitro systems often fail to recapitulate the 
3D structure of the microenvironment, cellular diversity 
and biomechanical cues of real tissue.
Because of the limitations of conventional in vitro cell-
based assays for NM testing, researchers have imple-
mented microfluidic platforms that can more closely 
resemble real in  vivo conditions (Fig.  7). Some of the 
advantages of microfluidic devices are: (1) well-controlled 
perfusion of homogeneously dispersed NPs, (2) continu-
ous perfusion of fresh nutrients and removal of waste 
materials, (3) cell-volume to fluid ratio closer to physio-
logical values, (4) fast and seamless switch between solu-
tions to perform chronic and acute exposures, (5) precise 
delivery of reagents and NPs to sub-populations of cells, 
(6) precise cellular manipulation and positioning for pat-
terning of multiple cell types in co-culture, (7) seamless 
generation of continuous concentration gradients of NPs, 
(8) generation of physiologically relevant mechanical 
stresses (e.g., shear forces) and (9) creation of dynamic 
and complex 3D environments.
Exposure to well-defined and homogeneous con-
centrations of nanomaterials is a paramount for reli-
able therapeutic and toxicological analyses [209]. In 
this regard, microfluidic platforms have been proven 
beneficial because the fluid drag force exerted on the 
nanoparticles circumvents particle sedimentation, 
buoyancy and agglomeration [211, 212]. Indeed, it has 
been demonstrated that quantum dot (QT)-induced 
cytotoxicity in fibroblasts is higher under static than 
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flow exposure conditions. The authors of this study 
suggested that the settling down of QD over the cells 
might induce additional physicochemical stresses that 
could account for increased cytotoxicity. Similarly, 
HeLa cells responded differently when exposed to Ag 
NPs in static vs. perfusion conditions [210]. In this 
case, perfusion of Ag NPs lead to enhanced cytotox-
icity by accelerating cell cycle arrest and subsequent 
apoptosis. Importantly, the cytotoxic effect augmented 
as the flow rate increased because of higher delivery of 
NP doses at faster flow rates with only a minor effect 
of the shear stress itself in cell viability.
Cytotoxicity of QDs has been also studied in neu-
ron-like pheochromocytoma cells using a two-com-
partment microfluidic device [213]. In this set-up, 
axonal outgrowths were guided into a fluidically iso-
lated compartment to study QD exposure locally in 
cell somas and axon terminals. Using this device, the 
authors found that cetyltrimethylammonium bro-
mide/trioctylphosphine oxide-modified QDs were 
cytotoxic, causing cell shrinkage and axonal degen-
eration. Furthermore, selective exposure of cell somas 
and axon terminals to toxic QDs suggested that axonal 
degeneration could be a consequence of neuronal cell 
death and local axonal toxicity. This approach illus-
trates how microfluidic devices can be used to tar-
get subcellular compartments for nanotoxicological 
studies.
Effect of shear stress in cellular uptake of NPs and toxicity
Endothelial cells (EC)s that line the luminal surface of 
blood and lymphatic vessels are constantly exposed to 
shear stress imposed by the flow of blood and lymph 
fluid, respectively. This mechanical stress acts on mecha-
nosensitive receptors to regulate cell behavior [214]. In 
this regard, microfluidic devices have been widely used to 
study the response of a monolayer of ECs to shear stress 
and its influence on cellular uptake/interaction of NPs. 
For instance, ECs exposed to unmodified mesoporous sil-
ica NPs at different physiologically relevant shear forces 
(5–6  N  m−2) exhibited increasing cytotoxic effects with 
increasing shear stress [215]. In contrast, highly organo-
modified mesoporous silica NPs was not cytotoxic even 
under flow conditions. In this study, the NP concentra-
tion was adjusted for each shear stress level to match 
the NP dose of static condition and thus avoiding higher 
Fig. 6 Static vs. dynamic conditions in cell‑based assays for nanotoxicology. a Nanoparticles (NP)s tend to agglomerate and sediment in 
traditional cell‑based assays performed under static conditions. This creates large particle agglomerates that are not readily taken up by cells. 
In addition, sedimentation generates concentration gradients. Therefore, delivered doses do not often match cellular doses (i.e., the amount of 
material in contact with and taken up by cells). b In contrast, cell‑based assays performed in microfluidic devices, i.e., under dynamic conditions, 
allow perfusion of homogeneous NP dispersions from reservoirs equipped with mechanical stirrers. In addition, the fluid shear stress decreases 
NP agglomeration and sedimentation within the microfluidic channels. These two factors can be further reduced by designing microchannels 
structured with microgrooves and herringbone‑microstructures to increase convective mixing
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delivery of NP doses with higher flow rates. Therefore, 
the observed increase in cytotoxicity of unmodified sil-
ica NPs with higher shear forces was attributed to the 
flow shear stress acting on ECs to change their behav-
ior. In fact, a later study demonstrated that ECs took up 
negatively charged CdTe QTs and silica nanoparticles 
under shear stress conditions, but not under static con-
ditions within 20  min of NP exposure [216]. Interest-
ingly, the authors of this study observed maximal cellular 
uptake of NPs at a shear stress value of 0.05 N m−2 and 
an increased number of cellular outgrows under shear 
stress conditions (e.g., filopodia and membrane ruffles) 
that may have facilitated the internalization of NPs. Fede 
et al. also demonstrated the relevance of shear stress for 
toxicological testing of Au NPs [217]. Here the authors 
observed that ECs exposed to citrate-stabilized Au NPs 
showed lower cytotoxic effects under flow conditions 
with respect to static exposure. Importantly, Fede et  al. 
showed that the viability of ECs decreases with increas-
ing total NP surface area per unit volume of solution, 
regardless of NP size.
Organic NPs such as lipidic, polymer- and protein-
based NPs, have been proposed as drug delivery vehicles 
for treatment of several diseases. Although their potential 
as drug carriers is widely recognized (for a review see 
[218]), to date, only a few of these nanocarriers have 
been commercialized for intravenous drug delivery (e.g., 
Abraxane—protein-bound Paclitaxel, and Doxil—a lipo-
somal formulation of doxorubicin). This highlights the 
need for relevant in vitro models for characterization and 
optimization of organic NPs as drug delivery vehicles.
An elegant study by Korin and coworkers demon-
strated how to exploit high shear forces, similar to those 
experienced in obstructed blood vessels, to deliver drugs 
for rapid clot dissolution [219]. In this study, microscale 
agglomerates of NPs made out of poly(lactic-co-glycolic 
acid) (PLGA) were design to break up into nanoscale 
components when exposed to abnormally high shear 
stress. PLGA aggregates were stable in aqueous solution, 
but broke apart when exposed to high shear stress in a 
microfluidic device that served as model to mimic regions 
of living blood vessels with 90% of lumen obstruction. 
Moreover, released NPs accumulated in ECs lining the 
surface of the artificial microfluidic vessel distal to the 
constricted region with minimal uptake in cells located 
before the constriction. Upon validation in the micro-
fluidic device, the authors investigated the therapeutic 
potential of NPs coated with the thrombolytic drug tissue 
Fig. 7 Schematic diagram depicting the components of the microfluidic platform developed in the GEMNS project (EuroNanoMed II program) by 
the Nanotoxicology group, University of Bergen, Norway. In this setup, custom‑made on‑chip reservoirs are directly attached to the chip inlets and 
the fluid is withdrawn continuously through the outlets using pulsatile‑free syringe pumps. The on‑chip reservoirs are automatically refilled with 
homogeneous nanoparticle dispersions every 30 min using a programmable pressure pump. To ensure dispersion homogeneity, the liquid reservoir 
of the pressure pump is kept under agitation using a magnetic stirrer with a stirring bar that does not interact with nanoparticles. The microfluidic 
device consists of four independent microfluidic chambers, each with a microelectrode array to evaluate the cytotoxicity via a cell‑substrate 
impedance sensing. Impedance measurements were performed sequentially using an electrode switch and a potentiostat
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plasminogen activator (tPA) in a mouse arterial throm-
bus model. In agreement with in vitro observations, tPA-
coated NPs preferentially accumulated in regions of clot 
formation (i.e., high shear stress) and induced rapid clot 
dissolution, restoring normal flow dynamics [219].
Lipidic NPs have been also studied under shear 
stress conditions to modulate drug delivery and cell 
interaction. For example, shear-stress sensitive lentil-
shaped liposomes were shown to release drugs locally 
at regions of elevated shear stress in a biomimicked 
model of atherosclerosis [220]. To enhance liposome 
interaction with ECs, liposomes can be functionalized 
with antibodies that recognize intercellular adhesion 
molecules expressed in ECs. For instance, Paulis and 
coworkers decorated liposomal MRI contrast agents 
with antibodies targeting the intercellular adhesion 
molecule-1 and analyzed their interaction with brain 
endothelial cells at physiologically relevant shear stress 
conditions [221]. The authors found that the higher the 
shear stress, the lower the efficiency of liposome-EC 
binding.
In a different study, Hosta-Rigau and Stadler made 
used of a microfluidic set-up to assess the response of 
mechanosensitive myoblast cells to liposomes, coated 
silica NPs and lipoplexes under static and low shear 
stress conditions (0.0146  N  m−2) [222]. The authors 
showed enhanced interaction between positively charged 
liposomes and poly-l-lysine-coated silica NPs in the 
presence of low shear stress in comparison to static con-
ditions. To note, irrespective of flow shear stress, zwitteri-
onic and negatively charged liposomes poorly interacted 
with myoblast cells. To further demonstrate the relevance 
of shear forces for drug delivery, the authors loaded the 
positively charged liposomes with the hydrophobic anti-
tumor compound thiocoraline and exposed the cells to 
this formulation in the presence of fluid flow. The results 
showed a circa 50% decrease in cell viability when thioc-
oraline-loaded liposomes were administered in the pres-
ence of low shear stress as compared to static conditions. 
Finally, this study also demonstrated that cationic lipid-
mediated gene delivery was more efficient when myoblast 
cells were exposed to shear stress than in static culture 
conditions. A similar study by Teo et  al., demonstrated 
no significant difference in the uptake of PEGylated posi-
tively charged or non-PEGylated liposomes by myoblasts 
under static and flow conditions [223]. By contrast, lipo-
some uptake by hepatocytes was significantly higher for 
non-PEGylated than PEGylated liposomes when exposed 
to shear stress. These results demonstrate the relevance 
of shear stress for studying the interaction of NPs not 
only on ECs, but also with other cell types that may come 
into contact with NPs because of biodistribution.
Taken together, all these studies emphasize the rel-
evance of microfluidic devices to biomimic the dynamic 
environment to which cells are exposed in vivo for reli-
able assessment of cytotoxic effects of NPs. They also 
demonstrate that blood flow-induced shear forces have 
to be considered for the design of nanocarriers for drug 
delivery and that microfluidic devices are ideal for bio-
mimicking this scenario.
Studying NP‑cell interactions in microengineered 
biomimetic models
Organs-on-chips are microengineered cell culture mod-
els that replicate cellular composition, microenvironment 
architecture, mechanical cues and physiological func-
tion of key units of living human organs. Consequently, 
organs-on-chips are now being implemented as means to 
obtain reliable predictions of drug efficacy and NP cyto-
toxicity. Pioneering work by Huh et  al., demonstrated 
the use of a lung-on-a-chip model for nanotoxicological 
testing under physiologically relevant conditions [188]. 
They microengineered the alveolar-capillary interface in 
a microfluidic device by co-culturing human alveolar epi-
thelial and human pulmonary microvascular endothelial 
cells in opposite sides of a thin porous elastomeric mem-
brane. The membrane served as the interface between the 
upper alveolar and lower microvascular chambers of the 
microfluidic device. Furthermore, mechanical actuation 
of the elastomeric membrane was implemented to mimic 
physiological breathing motions. This biomimicking 
approach revealed that cyclic mechanical strain enhances 
toxic and inflammatory responses of the lung to silica 
NPs. In addition, mechanical strain enhanced the cellular 
uptake of NPs by epithelial and endothelial cells, which 
facilitated the transport of NPs into the lower microvas-
cular chamber. Interestingly, silica NPs and Cd/Se QDs 
induced the production of reactive oxygen species in 
both cellular layers under mechanical stress. By contrast, 
superparamagnetic Fe NPs, Ag NPs, polystyrene NPs, 
singled-wall carbon nanotubes and PEG-coated QDs did 
not induce an oxidative response.
In a later study, Kim and coworkers developed a blood 
vessel-on-chip model to study NP translocation across 
a dysfunctional endothelial barrier in experimental ath-
erosclerosis [224]. Their device consisted of an upper 
and lower microfluidic chamber interfaced by a thin 
semiporous membrane. ECs were grown in the upper 
chamber and a leaky endothelial barrier characteristic of 
atherosclerosis was induced by perfusion of TNFα and 
low shear stress (< 0.4  N  m−2). Under these conditions, 
PEGylated liposomes readily translocated across the dys-
functional endothelial barrier. Importantly, the results 
obtained with the microfluidic devices were corroborated 
by data from animal models.
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NP transport from capillaries into surrounding tissues 
has been also addressed using biomimetic microfluidic 
devices. For instance, Wu et al. fabricated a device com-
prising a main chamber, representing a blood vessel, and 
two sets of side cell culture chambers. The main and side 
chambers were interconnected by stop-flow junctions 
that only permit mass transport by means of diffusion. In 
this device, human hepatocellular liver carcinoma cells 
were grown in the side cell culture chambers embed-
ded in an agarose matrix and QDs were perfused in the 
main chamber. The results of this study revealed a dose-
dependent increase in the cytotoxic effects of QDs. In 
addition, it was shown that cell autophagy played a key 
role in QD cytotoxicity.
Incorporating tumor spheroids into microfluidic 
devices will help to better understand NP penetration 
into solid tumor tissue and thus improve NP design for 
enhanced drug delivery. In this regard, Albanese and 
coworkers developed a tumor-on-a-chip system con-
sisting of a multicellular spheroid immobilized within a 
microfluidic channel that allowed continuous perfusion 
of Au NPs [225]. The spheroid was composed of mela-
noma cells embedded in an extracellular matrix form-
ing a tortuous network of interstitial spaces. The authors 
showed that penetration of NPs into the tumor tissue 
is diffusion-limited and dependent on NP size; while 
NPs < 110 nm can diffuse through the ECM and interact 
with melanoma cells, NPs > 110  nm mainly localize to 
the periphery of the spheroid. In addition, NP retention 
within the tumor interstitium can be improved by recep-
tor targeting. Notably, a murine tumor model corrobo-
rated the findings from the tumor-on-a-chip device.
Future perspectives
Microfluidic systems have a potential, by enabling earlier 
cancer molecular diagnosis, for a better targeted cancer 
therapy and improved follow-up care, to make the care 
process more effective in terms of clinical outcome for 
cancer patients’ needs. The application of microfluid-
ics to novel diagnostics and anticancer drug design has 
demonstrated a significant impact on many areas of 
modern nanomedicine. It is becoming increasingly more 
evident from the number of ongoing research programs 
that microfluidic systems play a pivotal role in personal 
nanomedicine. Perhaps one of the essential areas of the 
research in personalized nanomedicine to move for-
ward is the development of the point-of-care (POC) 
diagnostics based on novel microfluidic platforms to 
help assign particular early molecular diagnostics and 
target treatment schedules to individuals with diseases 
such as lung cancer. Therefore, microfluidic devices will 
be further developed from the bench-to-bedside and 
updated to produce patient-friendly analytical assays. 
Impedance-based measurements could be applied in 
microfluidic systems to enable a quick screening of sin-
gle lung cancer cells in order to identify their metastatic 
potential. To speed up the analysis and make it patient 
friendly, the so-called paper-based microfluidic devices 
and lab-on chips based on paper imprinting technol-
ogy will be developed [226]. Their real advantage will 
be the simplicity of design and ease of interpretation of 
test results regarding POC diagnostics [227]. Combining 
both microfluidic and bioprinting technology will consti-
tute growing areas in upcoming future. Such bioprinting 
technologies will be improved by bioengineering of 3D 
constructs that mimic tumor heterogeneity, vasculature 
and spheroid structures. Furthermore, bioprinting pro-
cesses will be used to fabricate cancer tissue constructs 
within microfluidic platforms, forming lung tumor-on-a-
chip devices which are ideal for high-throughput testing 
in a biomimetic microenvironment.
Microfluidic devices for assessing the impact of the 
surrounding microenvironment and circulating tumor 
cells detection have been widely described in the litera-
ture. The progress of the latter is extremely dynamic due 
to their diagnostic potential and the possibility to use as 
POC. The progress in microengineering manifests also 
in more comprehensive devices that recapitulate organs 
and cancers’ environments in vivo, processes like metas-
tasis and carcinogenesis allow the testing of conventional 
anticancer drugs, theranostics and nanoparticles as well 
as studying the nanosafety. Although, the development in 
microfluidic devices is going fast, the ideal microfluidic 
system that would perfectly imitate in  vivo metastasis 
conditions has not yet been created, hence there are still 
limitations that need to be addressed. Modern microflu-
idic chips are equipped with automated continuous flow 
running of biofluid, stable gradient maintenance and con-
tinuous digital cell behavior registration [78]. Microflu-
idic devices with a greater potential to reproduce in vivo 
conditions possess biocompatible membranes with pores 
[76] and/or other microunits that may constitute the 
scaffold for endothelium [76] aimed at building up real 
structures occurring in organism.
In order to improve currently existing microfluidic 
devices, aspects like (1) imitation of in vivo tumor con-
ditions, (2) automatization and digitization of essential 
components of medium supply, and (3) microdevice with 
integrated functions of analytical and omics techniques 
still need to be considered. In order to create in vivo con-
ditions an adequate material for microfluidic construc-
tion need to be selected. The stiffness of the material as 
well as its biocompatibility will affect cells culturing. The 
spatial construction of a device should enable cells cul-
turing in multilayers for accurate mimicking of a solid 
mass tumor. A spherical structure of a tumor reproduced 
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by cells in artificial conditions provides a recapitulation 
of cells’ morphology, cell–cell and cell-ECM interac-
tions which have a great impact on differentiation, pro-
liferation, expression the genes and proteins, response 
to stimuli, drug metabolism and other cellular functions 
[191]. The selection of appropriate biofilm like gel or 
culturing in a scaffold is essential for 3D cells conforma-
tion establishment [191]. In order to study metastasis, 
the tumor cells need to interact with different tissues like 
(a) the epithelium layer (necessary for transendothelial 
cell migration), (b) potential places of metastatic niche 
development. The above aim would among others be 
obtained with  the aid of bioprinting technologies 3D 
constructs that mimic tumor heterogeneity, vascula-
ture and spheroid structures. Cells, as well as develop-
ing tumors, need a constant and controllable supply of 
oxygen, nutrients, metabolites and signal molecules in a 
biofluid under defined shear stress [191], as well as drain 
of toxic metabolic products. Those processes need to be 
automatized. The investigation of the biochemistry of the 
tumor needs working with chemical gradients and elec-
trical stimuli that also should be automatized in order to 
be stable and reproducible. Finally, microdevices should 
be equipped with constant digital registration of cells’ 
behavior. Creation of program for cell type identification 
would enable resignation from cells staining and fixing 
allowing their continuous tracking. In the study upon 
metastasis it is also important to apply “from the bench-
to-bedside” rule. Efforts have been put into in vivo condi-
tions reconstruction into one chip, however there is also 
a possibility to use similar chips in human organism. For 
example, a chip that serves for CTCs detection could be 
installed into the body of a person with cancer suspicion 
or recurrence. After the detection of CTC the microflu-
idic device would automatically send the information 
to other electronic devices (Fig.  8). Other possibility is 
patient friendly, paper-based microfluidic device that 
could serve for lung cancer determination. There is also a 
need to deeply develop microfluidic devices for personal-
ized toxicity studies. The proposition is even more actual 
in a view of growing air pollution and spreading smog 
responsible for lung disease including cancer. In this case 
it would be even a life-saving device.
The miniaturization of analytical and omics tech-
niques has been previously predicted [1], however there 
is still a need of incorporation all these techniques into 
single microdevice. Progress in this field is noticeable 
since microdevices for DNA nanotechnology [231] and 
proteomic and metabolomic profiling [232] have been 
recently developed, however for maintaining reproduc-
ibly and repeatability of the results and eliminating cells 
contamination and errors related to material processing 
Fig. 8 Recent progress of microfluidic technologies in nanomedicine. The figures are reproduced from El‑Ali et al. [228] with permission of Nature, 
Kong et al. [44] with the permission of Oncotarget, Long et al. [229] with the permission of Annals of Biomedical Engineering, Palaninathan et al. 
[230] with permission of MRS Communication
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all techniques should be combined in a way of merging 
cell handling with analytical, biochemical and molecular 
determination.
Improving the ability to predict the efficacy and toxicity 
of new anticancer drugs including theranostic nanoma-
terials earlier in the drug discovery process will speed up 
the introduction of novel drug candidates into clinical tri-
als. Note that 3D in vitro systems placed on microfluidic 
devices will significantly support the new drug screen-
ing process as the 3D tissue cancer models can closely 
mimic the native tissues and, in some cases, the physi-
ological response to novel drug molecules [233]. There-
fore, microfluidic systems will be an essential approach 
to address many unmet lung cancer diagnostic and thera-
peutic needs in the coming future.
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